Ibrutinib launched for treatment of mantle cell lymphoma and chronic lymphocytic leukaemia Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has been launched in the UK for the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia.…
Medicines regulator amends conflict of interest rules to ensure suitability of experts The European Medicines Agency has amended its policy on handling declarations of interest to ensure pharmaceutical experts are not unduly excluded.…
EllaOne to be available without prescriptionEllaOne (ulipristal acetate), an emergency contraceptive, is to be made available without a prescription from community pharmacies throughout the European Union.…
EU and US criticise Russia over protectionist measures for its pharmaceutical industry The European Union (EU) and the United States have criticised Russia’s move away from open trade and introduction of policies that discriminate against foreign imports, including pharmaceuticals and medical devices.…
Pipeline November 2014 The latest approvals and positive opinions from the European Medicines Agency.…
Optimising therapy for inflammatory bowel disease How to tailor treatment for patients and ensure optimum management of Crohn’s disease and ulcerative colitis.…
Exploring the history of generic medicines ‘Generic: the unbranding of modern medicine’ by Jeremy A Greene.…
Breastfeeding mothers may lose out if recent domperidone warnings are heededThe benefits of using domperidone to increase milk supply in breastfeeding mothers outweigh its risks, argues a researcher at the University of Adelaide, South Australia.…
Selective COX-2 inhibitors linked to worse outcomes after ischaemic stroke New research suggests that selective cyclooxygenase-2 inhibitors herald worse outcomes following ischaemic stroke.…
NHS expenditure on prescribed medicines up by 7.6%, with 15.1% increase in hospital sector The cost of medicines prescribed by hospitals in England increased by 15.1% to £5.8bn in 2013–2014 compared with the previous year.…